---
target_keyword: psychedelic therapy real-world evidence data platform
seo_title: PPN Portal: Institutional RWE Data Ecosystem for PAT Research
seo_meta_description: De-identified, ontology-standardized cohort data from real-world psychedelic-assisted therapy practice. IRB-ready. 21 CFR Part 11 compliant. Zero PHI.
aio_schema_type: Product
aio_schema_description: PPN Portal is a Zero-PHI clinical data platform for psychedelic-assisted therapy that enforces RxNorm, MedDRA, and SNOMED ontologies at point of capture, producing IRB-ready, 21 CFR Part 11-compliant longitudinal cohort datasets without manual curation.
internal_links:
  - anchor_text: "Request Data Access"
    target_url: "mailto:info@ppnportal.net?subject=PPN Research Data Access Request"
---

# CONTENT MATRIX — GO-650
## Researcher Digital Leave-Behind (Institutional RWE Portfolio)
**Audience:** Academic researchers, Principal Investigators, CROs, IRB members, data scientists
**Notebook session:** 8a6ab54f
**Screenshot audit date:** 2026-03-20

---

## Hero Section

**Eyebrow:** PPN Portal: Institutional Research Division

**Headline:**
The PPN Data Ecosystem:
Institutional RWE and Telemetry Portfolio

**Subhead (italic):**
Enabling clean, longitudinal, Zero-PHI data aggregation for psychedelic meta-analysis.

**Body copy:**

The data bottleneck in psychedelic research is not sample size. It is data structure. Current longitudinal studies are bottlenecked by legacy Electronic Health Records (EHRs) that rely on unstructured, free-text clinical notes, requiring thousands of hours of manual coding before any dataset can enter a statistical pipeline. The presence of Protected Health Information (PHI) further limits cross-site data sharing and population-level benchmarking.

The Psychedelic Practitioner Network (PPN) solves this by enforcing strict, validated ontologies (`RxNorm`, `MedDRA`, `SNOMED CT`) at the point of clinical capture. With a Zero-PHI, cryptographically hashed architecture, PPN aggregates Real-World Evidence (RWE) across independent clinical sites without triggering HIPAA data-sharing violations or requiring IRB amendments.

**The following portfolio presents a curated sample of our automated research exports and telemetry dashboards.**

---

## Architecture Callout Strip (3 cells)

| Label | Content |
|---|---|
| **Ontology Standards** | All adverse events mapped to MedDRA Preferred Terms. Medications coded as `RxNorm CUIs`. Diagnoses in SNOMED CT. Zero free-text in structured fields. |
| **Data Integrity** | 21 CFR Part 11 compliant. Cryptographic hash chain per record. Immutable audit trail from point of capture. IRB-ready without manual curation. |
| **PHI Architecture** | Zero PHI stored. Cryptographic `Subject_ID` replaces all identifiers. Cross-site aggregation is possible without IRB data-sharing amendments. |

---

## Module 1: RWE and Cohort Analytics

**Module label:** Module 1: Real-World Evidence

**Module title:** RWE and Cohort Analytics

**Module tagline:** Clean, structured, longitudinal cohort data aggregated across independent clinical sites, ready for SPSS, R, or Python without manual wrangling.

### Exhibit 1A: Research Outcomes Export
**Screenshot file:** *(PDF export, placeholder — no screenshot available)*
**NotebookLM source:** Research Export — RES-2026Q1-PSIL

**Card title:** Research Outcomes Export (RES-2026Q1-PSIL)

**Description:** De-identified, IRB-ready aggregate data for a psilocybin cohort (n=24, treatment-resistant MDD, 3-site aggregated). Contains baseline vs. final PHQ-9 and GAD-7 delta scores, responder and remission rates by MADRS threshold, and CTCAE-graded adverse event summary. Structured fields, no free-text paragraphs.

**Callout:** Facilitates immediate extraction of IRB-ready, de-identified aggregate cohort data adhering to HIPAA Safe Harbor standards, accelerating multi-site comparative efficacy analyses.

---

### Exhibit 1B: Outcome Forecast Confidence Cone
**Screenshot file:** `marketing-screenshots/webp/Outcome Forecast Confidence Cone.webp`
**NotebookLM source:** Outcome Forecast Confidence Cone.png

**Card title:** Outcome Forecast Confidence Cone

**Description:** A predictive chart projecting a patient's expected longitudinal recovery trajectory against the multi-site community mean (N=14K), with modeled confidence interval bands illustrating statistical uncertainty across the treatment arc.

**Callout:** Leverages a centralized multi-site aggregate dataset (N=14K) to project predictive longitudinal efficacy trajectories alongside precisely modeled confidence intervals.

---

### Exhibit 1C: Patient Outcome Constellation
**Screenshot file:** `marketing-screenshots/webp/Patient Outcome Constellation Combined.webp`
**NotebookLM source:** Patient Outcome Constellation Combined.png

**Card title:** Multivariate Patient Outcome Constellation

**Description:** A multi-dimensional scatter plot mapping patient outcomes (remission, partial response, non-response) against baseline treatment resistance and symptom severity scores. Designed for cohort stratification without manual data cleaning.

**Callout:** Enables multivariate spatial stratification of cohorts by mapping baseline treatment resistance against symptom severity, allowing isolation of significant patterns in protocol efficacy.

---

## Module 2: Telemetry and Pharmacokinetics

**Module label:** Module 2: Advanced Telemetry

**Module title:** Telemetry and Pharmacokinetics

**Module tagline:** Standard EMRs track appointments. PPN captures the pharmacological context, physiological telemetry, and structured psychological state data required for mechanism-of-action modeling.

### Exhibit 2A: Session Timeline Export
**Screenshot file:** `marketing-screenshots/webp/Symptom Decay Curve Timeline.webp`
**NotebookLM source:** Session Timeline — STL-20260319-A1B2
**Note:** Session Timeline PDF not available in screenshot library. Symptom Decay Curve Timeline is the closest available substitute showing longitudinal structured data output.

**Card title:** Structured Session Timeline Export

**Description:** A time-stamped, structured event ledger from a live dosing session synchronizing physiological telemetry (vital signs, autonomic indicators) with clinical observations, correlated against a standardized pharmacokinetic arc from onset through resolution.

**Callout:** Synchronizes time-stamped physiological telemetry with structured clinical observations against a standardized pharmacokinetic model to comprehensively map acute subjective effects.

---

### Exhibit 2B: Molecular Binding Affinity Matrix
**Screenshot file:** `marketing-screenshots/webp/Molecular Binding Affinity Matrix.webp`
**NotebookLM source:** Molecular Binding Affinity Matrix.png

**Card title:** Molecular Binding Affinity Matrix

**Description:** A high-density pKi heatmap comparing 10 psychedelic compounds against key receptor families (5-HT2A, 5-HT2C, D2, NMDA, kappa-opioid, sigma-1). The pharmacological reference frame PPN uses to contextualize all session-level clinical observations.

**Callout:** Presents a high-density pKi heatmap quantifying binding affinities across multiple 5-HT, DA, and NMDA receptor systems to contextualize receptor-mediated outcomes in structured clinical data.

---

### Exhibit 2C: Substance Monograph — Mechanism of Action
**Screenshot file:** `marketing-screenshots/webp/Substance Monograph - 6 Technical Data.webp`
**NotebookLM source:** Substance Monograph — 2 Mechanism.png

**Card title:** Substance Monograph: Mechanism of Action

**Description:** A six-panel deep-dive into the neurobiological mechanism of a specific compound, including 5-HT2A agonism profile, Default Mode Network disruption hypothesis, safety and contraindication flags, and clinical efficacy trends drawn from published literature. Used to establish standardized physiological context across sites.

**Callout:** Outlines precise mechanisms of action and therapeutic hypotheses to establish a standardized neurobiological context for investigators across independent clinical sites.

---

## Module 3: Data Integrity and Audit Standards

**Module label:** Module 3: Data Integrity

**Module title:** Data Integrity and Audit Standards

**Module tagline:** Every data point in PPN is immutably hashed and timestamped at the moment of capture. Datasets are audit-ready for IRB and FDA review without requiring any manual curation.

### Exhibit 3A: Clinical Record Audit Logs
**Screenshot file:** `marketing-screenshots/webp/Clinical Record Audit Logs.webp`
**NotebookLM source:** Clinical Record Audit Logs.png

**Card title:** Clinical Record Audit Ledger (21 CFR Part 11)

**Description:** A comprehensive, cryptographically secured ledger logging every system access, data entry, protocol update, and alert — each entry hashed to provide mathematically verifiable proof of non-repudiation. Designed to satisfy FDA and EMA data provenance requirements for regulated clinical environments.

**Callout:** Maintains continuous 21 CFR Part 11 compliance via an immutable, cryptographically hashed ledger that captures all systemic access and data modification events.

---

### Exhibit 3B: CTCAE-Graded Adverse Event Report
**Screenshot file:** `marketing-screenshots/webp/Clinical Record Audit Logs.webp`
**NotebookLM source:** AE Report — AE-20260319-B7F3
**Note:** Adverse event report is a PDF export with no dedicated marketing screenshot. Using Audit Logs screenshot as Module 3 has full audit exhibit coverage. DESIGNER may substitute with Phase2.3.3-Form-Adverse-Events.webp from old screenshot library if preferred.

**Card title:** Adverse Event Report: MedDRA and CTCAE v5.0

**Description:** Every adverse event captured in PPN is automatically mapped to the MedDRA Preferred Term hierarchy and graded to CTCAE v5.0 severity criteria at the moment of entry. Structured fields, not clinical prose. Regulatory notification tracking included as a structured field.

**Callout:** Standardizes post-session safety documentation using established CTCAE grading ontologies, ensuring high-fidelity data capture and regulatory submission readiness across all contributing sites.

---

### Exhibit 3C: Zero-PHI Architecture — Phantom Shield
**Screenshot file:** `marketing-screenshots/webp/Start a Wellness Session - Select Patient.webp`
**NotebookLM source:** Start a Wellness Session — Select Patient.png

**Card title:** Zero-PHI Architecture: Phantom Shield Anonymization

**Description:** The platform's session initialization screen demonstrates the Zero-PHI architecture in action. Clinicians start sessions using a synthetic `Subject_ID` generated by the "Phantom Shield" cryptographic anonymizer. No patient name, date of birth, or identifier ever enters the structured database layer.

**Callout:** Employs a Zero-PHI architecture utilizing cryptographic anonymization to completely decouple clinical data analysis from protected health identifiers, enabling cross-site aggregation without IRB data-sharing amendments.

---

## Footer

**Body copy:** When a data scientist or Principal Investigator reviews this portfolio, they will recognize a platform built by someone who understands how clinical trials actually work. PPN speaks the exact language of RWE infrastructure: **ontology standards, CTCAE grading, 21 CFR Part 11 compliance, and Zero-PHI architecture.**

**Primary CTA button:** Request Data Access
**Primary CTA href:** `mailto:info@ppnportal.net?subject=PPN Research Data Access Request`

**Secondary CTA button:** Download Full Portfolio (PDF)
**Secondary CTA href:** `PPN_Researcher_Data_Portfolio.pdf` (download)

**Legal line:** © 2026 PPN Portal · ppnportal.net · Institutional Research Division · Confidential and Proprietary

---

## Screenshot Availability Summary

| Exhibit | File | Available |
|---|---|---|
| Research Outcomes Export | PDF only | ⚠️ Placeholder |
| Outcome Forecast Confidence Cone | `Outcome Forecast Confidence Cone.webp` | ✅ |
| Patient Outcome Constellation Combined | `Patient Outcome Constellation Combined.webp` | ✅ |
| Session Timeline | `Symptom Decay Curve Timeline.webp` (substitute) | ✅ sub |
| Molecular Binding Affinity Matrix | `Molecular Binding Affinity Matrix.webp` | ✅ |
| Substance Monograph - Mechanism | `Substance Monograph - 6 Technical Data.webp` | ✅ |
| Clinical Record Audit Logs | `Clinical Record Audit Logs.webp` | ✅ |
| AE Report | `Phase2.3.3-Form-Adverse-Events.webp` or Audit Logs | ⚠️ No dedicated marketing shot |
| Phantom Shield / Zero-PHI | `Start a Wellness Session - Select Patient.webp` | ✅ |

> [!NOTE]
> DESIGNER should capture a dedicated marketing screenshot of the Adverse Event Report form (Phase 2 dosing screen) and add it to `marketing-screenshots/webp/` to replace the substitute used in Exhibit 3B.
